Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Back to Search
Print
Bookmark Trial

NCT00637780

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
University Hospitals Case Medical Center
Cleveland, Ohio, 44106, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Juvenile Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.

- Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).

- Onset of JIA must have occurred prior to the patient's 16th birthday.

- Patients must weigh at least 20 kg.

- Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patient currently with systemic features of systemic JIA.


- Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.


- History of sensitivity to heparin or heparin-induced thrombocytopenia.


- Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as
required by protocol

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Juvenile Rheumatoid ArthritisStudy To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
NCT00637780
  1. Cleveland, Ohio
  2. Guadalajara, Jalisco
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Juvenile Rheumatoid ArthritisA Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
NCT00807846
  1. Tucson, Arizona
  2. Little Rock, Arkansas
  3. San Diego, California
  4. Hartford, Connecticut
  5. Washington, District of Columbia
  6. Delray Beach, Florida
  7. Delray Beach, Florida
  8. Miami, Florida
  9. Honolulu, Hawaii
  10. Honolulu, Hawaii
  11. Louisville, Kentucky
  12. Louisville, Kentucky
  13. Louisville, Kentucky
  14. Louisville, Kentucky
  15. Omaha, Nebraska
  16. Omaha, Nebraska
  17. Akron, Ohio
  18. Hershey, Pennsylvania
  19. Santiago, RM
  20. Concepcion, VIII Region
  21. San Jose,
  22. San Borja, Lima
  23. San Isidro, Lima
  24. Manila,
  25. Manila,
  26. Moscow,
  27. Moscow,
  28. Smolensk,
  29. Smolensk,
  30. Belgrade,
  31. Nis,
  32. Pretoria, Gauteng Province
  33. CH-1011 Lausanne,
  34. CH-8032 Zuerich,
  35. Kharkiv,
  36. Kiev,
  37. Kyiv,
  38. Simferopol,
  39. Zaporizhzhya,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Juvenile Rheumatoid ArthritisA Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
NCT00652925
  1. San Diego, California
  2. Hartford, Connecticut
  3. Delray Beach, Florida
  4. Miami, Florida
  5. St. Petersburg, Florida
  6. Chicago, Illinois
  7. Chicago, Illinois
  8. Chicago, Illinois
  9. Glenview, Illinois
  10. Hinsdale, Illinois
  11. Merrillville, Indiana
  12. New Orleans, Louisiana
  13. Boston, Massachusetts
  14. Worcester, Massachusetts
  15. Omaha, Nebraska
  16. Livingston, New Jersey
  17. New Hyde Park, New York
  18. New York, New York
  19. Tulsa, Oklahoma
  20. Tulsa, Oklahoma
  21. Portland, Oregon
  22. Portland, Oregon
  23. Portland, Oregon
  24. Altoona, Pennsylvania
  25. Altoona, Pennsylvania
  26. Duncansville, Pennsylvania
  27. Hershey, Pennsylvania
  28. Johnstown, Pennsylvania
  29. Lancaster, Pennsylvania
  30. Milwaukee, Wisconsin
  31. Milwaukee, Wisconsin
  32. Leuven,
  33. Rio De Janeiro, RJ
  34. São Paulo, SP
  35. São Paulo, SP
  36. Rio de Janeiro,
  37. Saskatoon, Saskatchewan
  38. Århus N,
  39. Vandoeuvre-les-nancy,
  40. Berlin,
  41. Bremen,
  42. Halle,
  43. Hamburg,
  44. Hannover,
  45. Monterrey, Nuevo Leon
  46. Guadalajara,
  47. Lima,
  48. Lima,
  49. Lima,
  50. Vila Nova de Famalicao,
  51. Moscow,
  52. Moscow,
  53. Piestany,
  54. Ljubljana,
  55. Madrid,
  56. Madrid,
  57. Valencia,
  58. Stockholm,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
Official Title  ICMJE An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis
Brief Summary This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Juvenile Rheumatoid
Intervention  ICMJE Drug: Sulfasalazine
Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
Other Name: AZULFIDINE EN-tabs Tablets
Study Arms  ICMJE Experimental: 1
Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
Intervention: Drug: Sulfasalazine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 27, 2016)		2
Original Estimated Enrollment  ICMJE
 (submitted: March 11, 2008)		12
Actual Study Completion Date  ICMJE January 2014
Actual Primary Completion Date January 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.
  • Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).
  • Onset of JIA must have occurred prior to the patient's 16th birthday.
  • Patients must weigh at least 20 kg.
  • Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day

Exclusion Criteria:

  • Patient currently with systemic features of systemic JIA.
  • Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Mexico,   United States
Removed Location Countries Canada
 
Administrative Information
NCT Number  ICMJE NCT00637780
Other Study ID Numbers  ICMJE A0031005
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP